ArticleFrontiers in genetics2026
Preliminary examination of noncoding mutations of esophageal squamous cell carcinoma in African Americans.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of esophageal squamous cell carcinoma is geographically heterogeneous and exhibits complex genomic features. We aimed to preliminarily analyze noncoding mutations identified through whole-exome sequencing. Agilent SureSelect XT Human All Exon V6+UTR was used to capture the exome library from 10 African American ESCC patients. After calling variants, we analyzed noncoding mutations using Variant Effect Predictor, CScape-somatic, HumanBase modules and Opencravat. Pathway enrichment analysis was performed using the SIGNOR database via the NDEx IQuery web tool. Our results identified noncoding variants in the 3'UTR, 5'UTR, splice site, and promoter regions. We also observed a nominal enrichment of germline variations in DNA damage repair genes among patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.